All In Biotech

Drug Trial Radar · NCT07934719

Mass Balance and Absolute Bioavailability of [14C]-VH4011499

A Phase 1, Open-label, Single-dose Study to Assess the Absolute Bioavailability, Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]-VH4011499 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Feb 18, 2027

Study completion Feb 18, 2027

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the trial is to characterize the absorption, metabolism, and excretion of \[14C\]-VH4011499, and to evaluate the absolute bioavailability of VH4011499.

Conditions

  • HIV Infections

Interventions

  • VH4011499Drug

    VH4011499 will be administered orally.

  • [14C]-VH4011499 (IV)Drug

    \[14C\]-VH4011499 will be administered as an iv infusion.

  • [14C]-VH4011499 (oral)Drug

    \[14C\]-VH4011499 will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Radioactivity (TRA) of the Cumulative Amount of Drug Excreted in Urine (Ae urine)Time frame: Up to 70 days
  2. TRA of the Cumulative Amount of Drug Excreted in Feces (Ae feces)Time frame: Up to 70 days
  3. Cohort 2 Only: TRA of the Cumulative Amount of Drug Excreted in Vomitus (Ae vomit)Time frame: Up to 70 days
  4. TRA of the Total Amount of Drug Excreted (Ae total)Time frame: Up to 70 days
  5. Fraction of the Administered Radiolabeled Dose Excreted in Urine (fe urine) as Total Drug Related MaterialTime frame: Up to 70 days
  6. Cohort 2 Only: Fraction of the Administered Radiolabeled Dose Excreted in Feces (fe feces) as Total Drug Related MaterialTime frame: Up to 70 days
  7. Cohort 2 Only: Fraction of the Administered Radiolabeled Dose Excreted in Vomitus (fe vomit) as Total Drug Related MaterialTime frame: Up to 70 days
  8. Fraction of the Administered Radiolabeled Dose Excreted in Urine, Feces, and Vomitus (fe total) as Total Drug Related MaterialTime frame: Up to 70 days
  9. Maximum Observed Plasma Concentration (Cmax) of VH4011499Time frame: Up to 70 days
  10. Time to Attain Cmax (tmax) of VH4011499Time frame: Up to 70 days
  11. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of VH4011499Time frame: Up to 70 days
  12. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of VH4011499Time frame: Up to 70 days
  13. Cohort 1 Only: Cmax of [14C]-VH4011499Time frame: Up to 70 days
  14. Cohort 1 Only: Tmax of [14C]-VH4011499Time frame: Up to 70 days
  15. Cohort 1 Only: AUC0-t of [14C]-VH4011499Time frame: Up to 70 days
  16. Cohort 1 Only: AUC0-inf of [14C]-VH4011499Time frame: Up to 70 days
  17. Cmax of TRA in PlasmaTime frame: Up to 70 days
  18. Tmax of TRA in PlasmaTime frame: Up to 70 days
  19. AUC0-t of TRA in PlasmaTime frame: Up to 70 days
  20. AUC0-inf of TRA in PlasmaTime frame: Up to 70 days
  21. Cmax of TRA in Whole BloodTime frame: Up to 70 days
  22. Tmax of TRA in Whole BloodTime frame: Up to 70 days
  23. AUC0-t of TRA in Whole BloodTime frame: Up to 70 days
  24. AUC0-inf of TRA in Whole BloodTime frame: Up to 70 days
  25. Whole Blood-to-plasma Ratio of TRATime frame: Up to 70 days
  26. Cohort 2 Only: Ae urine of VH4011499Time frame: Up to 70 days
  27. Cohort 2 Only: fe urine of VH4011499Time frame: Up to 70 days
  28. Cohort 2 Only: Renal clearance (CLR) of VH4011499Time frame: Up to 70 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.